Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
AssigneeAcetylon Pharmaceuticals, Inc.
InventorsBrian NORTH, Steven QUAYLE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Claims20
A pharmaceutical combination comprising:
- (a) a histone deacetylase 6 (HDAC6) inhibitor of Formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein,
- ring B is aryl or heteroaryl;
- R1 is aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or C1-6-alkyl;
- and
- R is H or C1-6-alkyl;
- and
- (b) an aurora kinase inhibitor selected from the group consisting of alisertib, AT-9283, barasertib, ENMD-2076, MK-5108, MSC 1992371A, danusertib, and tozasertib, or pharmaceutically acceptable salts thereof.
A method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of
- (a) a histone deacetylase 6 (HDAC6) inhibitor of Formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein,
- ring B is aryl or heteroaryl;
- R1 is aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or C1-6-alkyl;
- and
- R is H or C1-6-alkyl;
- and
- (b) an aurora kinase inhibitor selected from the group consisting of alisertib, AT-9283, barasertib, ENMD-2076, MK-5108, MSC 1992371A, danusertib, and tozasertib, or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.